Provided by Tiger Trade Technology Pte. Ltd.

Immunic, Inc.

16.50
+0.40002.48%
Volume:147.69K
Turnover:2.43M
Market Cap:224.40M
PE:-4.13
High:16.83
Open:16.22
Low:16.20
Close:16.10
52wk High:17.43
52wk Low:5.06
Shares:13.60M
Float Shares:11.92M
Volume Ratio:0.87
T/O Rate:1.24%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-3.9979
EPS(LYR):-6.2414
ROE:-138.17%
ROA:-66.80%
PB:1.76
PE(LYR):-2.64

Loading ...

Immunic initiated with an Outperform at Wedbush

TIPRANKS
·
Aug 17

Wedbush Initiates Immunic at Outperform With $45 Price Target

MT Newswires Live
·
Aug 17

Sam Slutsky Initiates Buy on Immunic, Citing Late-Stage MS Program, Expansion into Progressive MS, and Strengthened Nurr1-Focused Pipeline

TIPRANKS
·
Aug 12

Analysts Offer Insights on Healthcare Companies: Immunic (IMUX), Legend Biotech (LEGN) and Sagimet Biosciences, Inc. Class A (SGMT)

TIPRANKS
·
Aug 12

Immunic Posts Investor Presentation Highlighting Vidofludimus Calcium Phase 3 MS Program

Reuters
·
Aug 11

Immunic Q2 Loss Per Share USD 0.80

THOMSON REUTERS
·
Aug 11

Immunic Q2 EPS $(0.80) Beats $(1.10) Estimate

Benzinga Earnings
·
Aug 11

Immunic reports Q2 EPS (80c), consensus ($1.16)

TIPRANKS
·
Aug 11

Immunic Q2 Net Loss Widens to $34.1 Million; Operating Expenses Rise to $35.3 Million

Reuters
·
Aug 11

Immunic Files Form 3 for Director Elena Ridloff, Reporting no Beneficial Ownership

Reuters
·
Aug 11

Top News Today/Canada: Barrick Settles Newmont Dispute, Clearing Way to List Its Gold Assets

Dow Jones
·
Aug 11

Immunic Appoints Elena Ridloff to Board of Directors

Reuters
·
Aug 11

Immunic Inc Expected to Post a Loss of $1.19 a Share - Earnings Preview

Reuters
·
Aug 03

Immunic Updates Corporate Strategy, Highlights Vidofludimus Plans

TIPRANKS
·
Jul 15

Immunic Publishes Investor Presentation Outlining Vidofludimus Calcium Phase 3 Program in Multiple Sclerosis

Reuters
·
Jul 14

Immunic Names CEO Erik Lundgren to Board After Tamar Howson Retirement Resignation

Reuters
·
Jul 07

Immunic Holds Annual Shareholder Meeting, Backs 6 Million-share Increase to Equity Plan

Reuters
·
Jun 30

Immunic joins H.C. Wainwright Neuro Perspectives Expert Summit fireside chat

Reuters
·
Jun 10

Immunic files Form 3 initial beneficial ownership statement for CEO Erik Lundgren

Reuters
·
Jun 02

Immunic publishes investor presentation on oral immunology pipeline led by vidofludimus calcium in multiple sclerosis

Reuters
·
Jun 01